Sequoia Capital Israel

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Neurowyzr is a company focused on enhancing brain health through a comprehensive healthcare platform. It specializes in the detection, diagnosis, therapy, monitoring, and prevention of brain decline. By offering a range of evidence-based tools, Neurowyzr empowers healthcare providers to promote awareness and facilitate positive changes in brain health. The company's approach emphasizes early intervention and the prevention of cognitive decline, aiming to shift societal perspectives on brain health and encourage proactive maintenance of cognitive well-being.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

HealiRNA develops infectious disease vaccines, tumor vaccines, cell therapy, and protein replacement. They provide mRNA drug research and development, production, clinical trial design, and data analysis services.

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

Huayuan Regenerative Medicine is the manufacture of implantable bioartificial organs. Huayuan Regenerative Medicine is committed to the research and development, production, and sales of clinical grade stem cells, biological tissue engineering products, and biomanufacturing. Their clinical products include urinary kidney precursor cells, dialysis equipment, and a biosynthetic artificial pancreas.

Rhegen is engaged in the research and development of mRNA medicine and gene therapy, focusing on synthetic biology technologies to create innovative mRNA drugs and vaccines. The company specializes in platform technologies essential for nucleic acid therapeutics, including mRNA design, synthesis, and non-carrier delivery methods. Rhegen applies these advancements to drug research and development, targeting various clinical indications such as functional protein defects, cancer, and infectious diseases. With a commitment to enhancing drug synthesis and developing novel drug targets, Rhegen aims to contribute significantly to the field of therapeutics, emphasizing both market potential and clinical value.

Alternative Bio is a biotechnology company focused on developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes.

GenAssist Therapeutics, founded in July 2020 by a team of leading scientists and industry experts, specializes in the development of gene therapy drugs utilizing advanced base editing technology. The company is focused on addressing neuromuscular diseases that currently lack effective treatments, particularly Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). GenAssist aims to provide permanent cures by precisely repairing disease-causing genes directly within patients' cells. The company holds global intellectual property rights to its proprietary Targeted AID-based Mutagenesis (TAM) technology, positioning it at the forefront of innovative solutions for a range of genetic disorders.

Frontera Therapeutics is a biotechnology company dedicated to developing and commercializing recombinant virus-based gene therapies. Its mission is to establish an affordable and scalable platform for producing high-quality rAAV therapies, targeting genetic disorders such as those affecting the eye, liver, metabolism, and neuromuscular systems.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.

Grit Science is a biotechnology company specializing in gene therapeutics, focusing on the research and development of liver-related genetic treatments. The firm is dedicated to creating innovative medical products that address clinical needs and enhance human health. Through its commitment to advancing biopharmaceutical technology, Grit Science aims to provide effective solutions in the field of genetic medicine.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

HemaCell is a biotechnology company specializing in cell therapy, specifically focused on regenerating hematopoietic lineages, which include blood and immune cells, through advanced in vitro techniques. Leveraging innovative stem cell reprogramming, editing, and differentiation technologies, HemaCell aims to address the critical shortage of platelets necessary for treating various diseases such as cancer, liver disease, critical illness, and hematological disorders. The company employs a unique platform that utilizes platelets as drug delivery carriers, facilitating the rapid establishment of induced pluripotent stem cells (iPSCs) and gene targeting technologies. In addition to platelet production, HemaCell is dedicated to developing novel therapeutic solutions for diseases associated with platelet abnormalities, thereby offering effective treatment options and addressing significant medical needs.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic (IVD) company based in Suzhou, China, with a research and development office in Singapore. Founded in 2019, the company specializes in developing advanced diagnostic platforms for the detection of infectious diseases, cancer, and chronic diseases. Its technology offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Virtue Diagnostics aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.

Atom Bioscience is a clinical-stage biotechnology company focused on developing innovative treatments for inflammatory and metabolic diseases. Its pipeline includes therapies for chronic gout and non-alcoholic steatohepatitis (NASH).

Vico Medical, established in 2018 and based in Wuhan, China, specializes in the development and production of medical devices aimed at treating cardiovascular and cerebrovascular diseases. The company offers a range of products, including atrial shunts, puncture systems, and occluders for patent foramen ovale, along with delivery systems and other related devices. Vico Medical focuses on providing innovative intervention treatment solutions for structural cardiovascular issues, contributing to the reduction of stroke and heart-related disease incidents.

METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.

SyMap Medical is focused on the development and manufacturing of innovative medical devices aimed at treating hypertension and related diseases, including heart failure, arrhythmia, and severe asthma. The company specializes in a proprietary catheter-based renal mapping and ablation system that utilizes radiofrequency (RF) ablation technology. This system is designed for renal denervation therapy, which involves mapping and selectively ablating renal nerves to effectively manage hypertension. Through its advanced technology platform, SyMap Medical aims to address significant health challenges associated with major cardiovascular and respiratory conditions.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

ComGen Pharma is a biotechnology company that specializes in the research and development of innovative therapeutic drugs targeting the complement system. The company aims to create effective immunotherapies for autoimmune diseases and tumors by focusing on new and key targets within this biological pathway. Recently, ComGen Pharma secured nearly 100 million yuan in financing, which will primarily support phase I clinical trials for its complement inhibitors, advance its drug pipeline, and enhance its innovative drug research and development platform. The financing round was led by prominent investors, including Sequoia China and Yahui Investment, with additional support from Fuchuang Investment and Renyou Investment.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Cellular Biomedicine Group, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company employs proprietary cell-based technologies, including various forms of CAR-T therapy, which targets different cancer types, and human adipose-derived mesenchymal progenitor cells aimed at treating joint diseases. Its product pipeline features therapies such as CD20 and CD22 CAR-T for B cell malignancies, and alpha fetoprotein TCR-T targeting hepatocellular carcinoma. Additionally, Cellular Biomedicine is developing knee osteoarthritis treatments, including AlloJoin and Re-Join, the latter having completed Phase IIb trials. The company also engages in broader biopharmaceutical activities, encompassing research and development, technical support, and manufacturing of pharmaceutical polypeptides and medical devices. It has established a partnership with Novartis Pharma AG to produce and supply the CAR-T cell therapy Kymriah in China. Founded in 2001, Cellular Biomedicine Group is headquartered in New York, New York, and draws on a wealth of cellular medicine research and expertise from scientists and clinicians across the United States, England, and China.

Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.

Westlake Therapeutics is a biopharmaceutical company based in Hangzhou, China, founded in 2019. The company specializes in developing innovative cell therapies aimed at treating a range of human diseases, including cancer, rare disorders, and immunological and metabolic conditions. Central to its approach is the REDx platform, which enables the engineering of red blood cells and utilizes genetic modifications of hematopoietic stem and progenitor cells sourced from peripheral blood, bone marrow, or cord blood. This technology facilitates the creation of personalized treatment solutions, enhancing the potential for effective therapies tailored to individual patient needs.

Huayuan Regenerative Medicine is the manufacture of implantable bioartificial organs. Huayuan Regenerative Medicine is committed to the research and development, production, and sales of clinical grade stem cells, biological tissue engineering products, and biomanufacturing. Their clinical products include urinary kidney precursor cells, dialysis equipment, and a biosynthetic artificial pancreas.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Analytical Biosciences is a developer of single-cell genomics focused on creating precise maps of human diseases. The company collaborates with medical research institutions, hospitals, and pharmaceutical firms to leverage single-cell genomics and bioinformatics for improving disease diagnosis and treatment. By conducting large-scale systematic mapping of diseases at the single-cell level, Analytical Biosciences engages in extensive data mining to support its partners in discovering new therapeutic targets and developing innovative treatment strategies. Utilizing high-resolution databases and advanced data analytics, the company aims to unlock disease mechanisms and facilitate the identification and validation of novel cellular targets and biomarkers. This approach positions Analytical Biosciences at the forefront of advancing next-generation therapeutics and diagnostics.

Phanes Therapeutics is a biotechnology company specializing in drug discovery for immuno-oncology and eye diseases. Established in 2016, the company focuses on developing monoclonal antibodies for solid tumors and conditions like age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, they work on bispecific antibodies targeting small cell lung cancer.

Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

PackGene Biotech is a United States-based contract research organization and contract development and manufacturing organization that specializes in viral vectors for gene therapies. The company focuses on adeno-associated virus (AAV) vector design, cloning and packaging, as well as production of AAV, lentiviral vectors, mRNA, and plasmid DNA. It serves early-stage drug discovery, preclinical development, and cell and gene therapy trials, delivering scalable, cost-effective production with emphasis on purity, titer and infectivity. PackGene offers customized vector design, construction, and packaging services to support researchers in accelerating gene therapy programs.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.

D3 Bio, established in 2020, is a biotechnology company headquartered in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company's approach involves analyzing clinical and market data to identify gaps in current treatments, employing unique drug development methodologies to target new disease areas and routes, and ultimately providing patients with alternative therapeutic options.

PackGene Biotech is a United States-based contract research organization and contract development and manufacturing organization that specializes in viral vectors for gene therapies. The company focuses on adeno-associated virus (AAV) vector design, cloning and packaging, as well as production of AAV, lentiviral vectors, mRNA, and plasmid DNA. It serves early-stage drug discovery, preclinical development, and cell and gene therapy trials, delivering scalable, cost-effective production with emphasis on purity, titer and infectivity. PackGene offers customized vector design, construction, and packaging services to support researchers in accelerating gene therapy programs.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.

Dizal Pharmaceutical is a research-driven biotechnology company that specializes in the discovery, development, and commercialization of innovative medicines. The company focuses on creating first-in-class and best-in-class therapeutic solutions, emphasizing the development of groundbreaking drugs. With a commitment to advancing healthcare, Dizal engages in extensive research and development activities, alongside production and sales of its pharmaceutical products. Through its efforts, Dizal aims to contribute significantly to the pharmaceutical industry by delivering effective treatments that address unmet medical needs.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapy for cancer treatment. Founded in 2018 and headquartered in New Haven, Connecticut, the company utilizes directed evolution to create novel cytokines that enhance the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor effects in animal models, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. This innovative approach aims to provide patients with more effective immunotherapies, thereby improving their ability to fight cancer.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Atom Bioscience is a clinical-stage biotechnology company focused on developing innovative treatments for inflammatory and metabolic diseases. Its pipeline includes therapies for chronic gout and non-alcoholic steatohepatitis (NASH).

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

CERo Therapeutics is a biotechnology company focused on cellular immunotherapy and next-generation engineered T cell therapeutics for cancer. It develops platforms that integrate innate and adaptive immune programs to enhance anti-tumor activity and engage the body's full immune repertoire. The company was incorporated in 2016 and is headquartered in San Francisco, California. Its lead product, CER-1236, is an autologous T-cell therapy targeting a novel tumor antigen, TIM-4 ligand.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

RootPath Genomics, Inc. is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company specializes in developing a next-generation T-cell therapy platform that integrates precision medicine with cancer immunotherapy. By focusing on the analysis and manipulation of individual immune cells, RootPath aims to enhance immune responses and improve cell therapy efficacy. Its innovative technologies allow for precise monitoring and modulation of the immune system, which is intended to revolutionize the diagnosis and treatment of cancer.

ViGeneron develops innovative gene therapies focused on treating ophthalmic diseases with significant unmet medical needs. Its pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms: vgAAV, enabling superior transduction efficiency and less invasive treatment administration, and REVeRT, targeting diseases caused by mutations in large genes.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Cullgen Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics based on its uSMITE platform, which enables targeted protein degradation by using novel E3 ligands to selectively degrade disease-causing proteins. The approach aims to address cancers, inflammatory and autoimmune diseases, and other conditions lacking effective therapies. Founded in 2018 and based in San Diego, Cullgen's pipeline includes degrader programs such as TRK and GSPT1, as well as other candidates like DAC.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

BrightGene Bio-Medical Technology Company is a biopharmaceutical firm based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative medicines and high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company has a diverse product pipeline that includes immuno-oncological agents, GLP-1 receptor agonists for type 2 diabetes, and antibody-drug conjugates aimed at treating solid tumors and brain cancers. Additionally, BrightGene develops a variety of treatments such as Eribulin, Trabectedin, and various macromolecules and cytotoxic payloads. Its product offerings span multiple therapeutic areas, including oncology, cardiology, infectious diseases, and immunology. Founded in 2001, BrightGene has positioned itself as a leader in small molecules and nucleotide drugs, focusing on advancing therapeutics across all stages of development.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Beijing Deep Intelligent Pharma Technology Co., Ltd. specializes in leveraging artificial intelligence and blockchain technology to enhance drug discovery, development, and medical affairs for pharmaceutical companies. Founded in 2017 and based in Beijing, the company offers a range of products, including a multi-language medical machine translation engine, intelligent pharmacovigilance for risk management, and tools for creating multilingual educational materials. Deep Intelligent Pharma also provides AI-enabled solutions for medical writing, document review, and quality control, as well as a patient search ecosystem to facilitate medical and clinical research. Additionally, the company offers intelligent regulatory affairs solutions to streamline drug research and development processes. Operating globally, including in China, the United States, and Japan, Deep Intelligent Pharma aims to improve the efficiency and quality of the pharmaceutical development lifecycle.

RootPath Genomics, Inc. is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company specializes in developing a next-generation T-cell therapy platform that integrates precision medicine with cancer immunotherapy. By focusing on the analysis and manipulation of individual immune cells, RootPath aims to enhance immune responses and improve cell therapy efficacy. Its innovative technologies allow for precise monitoring and modulation of the immune system, which is intended to revolutionize the diagnosis and treatment of cancer.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

Eden Biologics is a biopharmaceutical company that focuses on developing biosimilars and providing contract development and manufacturing services to clients and partners in the biopharmaceutical industry. The company specializes in producing complex dosage forms, including oral solids, liquids, semi-solids for both prescription and over-the-counter products, as well as macromolecule biologics. Eden Biologics offers expertise in manufacturing biologics from cell line development through commercial production, with a global and regional regulatory affairs knowledge base to ensure affordability and accessibility of biopharmaceuticals worldwide.

Founded in 2018, Brii Biosciences is a biotechnology company dedicated to researching, developing, and commercializing medicines for chronic illnesses, with a primary focus on infectious diseases. Headquartered in Durham, North Carolina, the company operates additional offices in Shanghai and Beijing, China; and San Francisco, California.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

MabSpace Biosciences is a biotechnology company established in 2013, specializing in the discovery and development of innovative antibody-based therapeutics aimed at treating cancer and fibrotic diseases affecting the lungs, kidneys, and liver. Located in Biobay Suzhou, a notable biotech incubator in China, the company employs its proprietary immune tolerance breaking technology (IMBT) to generate lead antibodies with diverse epitopes. This technology allows MabSpace to develop therapeutics that target various components of the tumor microenvironment, enhancing treatment efficacy. The company has established multiple partnerships for antibody discovery and co-development, and it has advanced its lead antibody program, which includes a potentially best-in-class anti-PD-L1 antibody known for its unique pH-dependent binding and recycling properties. Additionally, MabSpace has developed a panel of second-generation immuno-oncology antibodies that facilitate the exploration of combination therapeutic interventions alongside its PD-L1 antibody.

CStone Pharmaceuticals, founded in 2015, focuses on developing and commercializing innovative immunotherapy and precision treatment drugs for cancer patients worldwide. Its pipeline comprises over a dozen candidates targeting various indications, with immuno-oncology at its core.

Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Moderna is a biotechnology company focused on messenger RNA therapeutics and vaccines. It develops mRNA-based medicines that instruct cells to produce therapeutic proteins or antibodies in vivo, targeting infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has built a broad pipeline with multiple development candidates across several modalities and a track record highlighted by a COVID-19 vaccine authorized in the United States. Moderna collaborates with major pharmaceutical and research partners, including AstraZeneca, Merck, Vertex, and Alexion, as well as academic institutions such as Harvard University and Karolinska Institutet. It maintains manufacturing collaborations with Lonza for mRNA production and Catalent for fill-finish, and engages with public sector and philanthropic supporters such as BARDA, DARPA, and the Gates Foundation. As of 2025, the company continued expanding its mRNA development program across infectious disease, oncology, cardiovascular, and rare genetic diseases.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Life Infinity is a health management company dedicated to providing personalized health services aimed at age-specific diagnosis, treatment, and disease prevention. The company focuses on systematic management of chronic diseases, delaying the effects of aging, and relieving symptoms associated with various health conditions. Additionally, Life Infinity offers specialized services in health regeneration, anti-aging medical treatments, and natural healing programs, enabling clients to access professional regenerative medicine services tailored to individual needs.

Founded in 2015, Orasis Pharmaceuticals specializes in developing corrective eye drops for treating presbyopia. Its lead product, CSF-1, improves near visual acuity by pupil modulation, eliminating the need for reading glasses.

Life Infinity is a health management company dedicated to providing personalized health services aimed at age-specific diagnosis, treatment, and disease prevention. The company focuses on systematic management of chronic diseases, delaying the effects of aging, and relieving symptoms associated with various health conditions. Additionally, Life Infinity offers specialized services in health regeneration, anti-aging medical treatments, and natural healing programs, enabling clients to access professional regenerative medicine services tailored to individual needs.

Dongri Zhongyi Guan is a chain organisation for TCM diagnosis and treatment that integrates Internet technologies with the fundamental principles of traditional TCM. Pediatric illnesses, andrological illnesses such as impotence, early ejaculation, prostate, etc., spleen and stomach illnesses, colds and flu, neck and lumbar illnesses, liver and gallbladder illnesses, and other illnesses are all treated by them.

Founded in 2001, Celon Laboratories is a Hyderabad-based pharmaceutical company specializing in the development, manufacturing, and marketing of niche therapy products. Its portfolio includes oncology and critical care products, available in various dosage forms, serving markets across Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe.

Akumentis Healthcare Ltd, founded in 2010 and based in Thane, India, is a prominent manufacturer of pharmaceutical products specializing in branded generics. The company holds a strong market position in various therapeutic areas, particularly in women's health, and offers a diverse range of healthcare solutions aimed at addressing challenging medical conditions. Its product portfolio includes treatments for anti-infections, infertility, gynecology, musculo-skeletal issues, gastroenterology, orthopedics, and dermatology, among others. As a subsidiary of Akums Drugs and Pharmaceuticals Ltd, Akumentis Healthcare is dedicated to delivering effective healthcare products that cater to specific needs in the market.

SyMap Medical is focused on the development and manufacturing of innovative medical devices aimed at treating hypertension and related diseases, including heart failure, arrhythmia, and severe asthma. The company specializes in a proprietary catheter-based renal mapping and ablation system that utilizes radiofrequency (RF) ablation technology. This system is designed for renal denervation therapy, which involves mapping and selectively ablating renal nerves to effectively manage hypertension. Through its advanced technology platform, SyMap Medical aims to address significant health challenges associated with major cardiovascular and respiratory conditions.

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

biomodal develops DNA sequencing tools and technology to enable advanced medicines, diagnostics, and personalized treatments. Its platform is designed to integrate with existing sequencing and computing platforms, enabling users to obtain complete genetic and epigenetic methylation information from DNA libraries in a single workflow.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".